Novabio Therapeutics
A developer of multimodal Treg cell therapies, targeting neurodegenerative, autoimmune, and metabolic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Novabio Therapeutics, established in Shanghai, China in 2022 by Dr. Mingqi Lu, is a clinical-stage biopharmaceutical company focused on developing therapies centered around regulatory T cells (Tregs). Dr. Lu, the founder and CEO, brings extensive experience to the firm, having graduated from the University of Connecticut, conducted postdoctoral research at Johns Hopkins and Mount Sinai Medical Schools, and held executive positions in various European, American, and Chinese pharmaceutical companies. His background includes serving as a clinical executive director, vice president, and chief medical officer, providing a foundation in both clinical development and corporate leadership.
The company's core scientific focus is on the research, development, and clinical application of Tregs to address unmet medical needs in autoimmune diseases (AID) and neurodegenerative diseases (NDD). The therapeutic strategy is based on the function of Treg cells, a specialized subgroup of T cells discovered in 1995, which play a crucial role in regulating immune responses and inhibiting pro-inflammatory cells. Novabio Therapeutics is developing a pipeline of multimodal Treg cell therapies designed to offer treatments for these complex conditions. The product pipeline includes polyclonal Tregs, CAR-Treg, TCR-Treg, and Universal Treg candidates.
To support its therapeutic development, the company has established several technology platforms. These include an immunology and molecular biology platform for target screening, a cell process development platform to produce clinical-grade Treg cells, and a gene editing platform to create enhanced and more accessible versions of Treg therapies. The company is currently advancing multiple drug candidates through its pipeline, including NP-001, NC001, and NP005. While Novabio Therapeutics has not publicly announced any funding rounds, it operates in a competitive landscape, with its U.S. entity noted as a sponsor of orphan designation.
Keywords: Treg cell therapy, autoimmune diseases, neurodegenerative diseases, clinical-stage biopharmaceutical, CAR-Treg, TCR-Treg, immunology, gene editing, cell therapy, polyclonal Tregs, molecular biology, orphan drug sponsor, NP-001, NC001, NP005, Dr. Mingqi Lu, Shanghai biotech, clinical development, T cell regulation, immune system diseases